Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming

Qi Wang, Alanna Vossen, Yasuhiro H Ikeda, Patricia Devaux

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, “one-cycle” MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.

Original languageEnglish (US)
JournalGene Therapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Induced Pluripotent Stem Cells
Measles virus
Measles
Genes
Sendai virus
Messenger RNA
DNA Viruses
RNA Viruses
Viral Proteins
Cell- and Tissue-Based Therapy
Green Fluorescent Proteins
Transgenes
Plasmids
Vaccines
Cellular Reprogramming
Genome
RNA
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming. / Wang, Qi; Vossen, Alanna; Ikeda, Yasuhiro H; Devaux, Patricia.

In: Gene Therapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{de1d7cddb6eb4f7ea3cb2c85c7fa57fb,
title = "Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming",
abstract = "Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, “one-cycle” MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.",
author = "Qi Wang and Alanna Vossen and Ikeda, {Yasuhiro H} and Patricia Devaux",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41434-019-0058-7",
language = "English (US)",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Measles vector as a multiple genes delivery platform facilitating iPSC reprogramming

AU - Wang, Qi

AU - Vossen, Alanna

AU - Ikeda, Yasuhiro H

AU - Devaux, Patricia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, “one-cycle” MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.

AB - Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, “one-cycle” MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=85061209209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061209209&partnerID=8YFLogxK

U2 - 10.1038/s41434-019-0058-7

DO - 10.1038/s41434-019-0058-7

M3 - Article

C2 - 30944113

AN - SCOPUS:85061209209

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

ER -